Navigation Links
Dutch Authorize Manufacture of Vaccinogen's New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial

FREDERICK, Md., May 7 /PRNewswire/ -- Vaccinogen Inc. said Dutch health authorities licensed it to manufacture its break-through OncoVAX anti-colon cancer vaccine, immediately clearing the path to more than $100 million of potential European sales.

The Dutch approval of the company's facility based in Emmen, The Netherlands also paves the way to its pivotal US FDA Phase IIIb clinical trial -- the final step before the vaccine can be sold in the United States.

"The facility can produce up to 3,500 vaccines annually, equivalent to $130 million in revenues," said Michael G. Hanna, Jr., Ph.D., Vaccinogen CEO. "That number only scratches the surface of potential demand for a Stage II colon cancer vaccine. One of every three patients who have their cancer removed see it return -- and the results are usually fatal."

"Our experience with OncoVAX has resulted in increasing the patients' chance of survival by more than 50%," he concluded. "This represents an opportunity for a new lease on life for tens of thousands of patients around the world."

The Dutch license permits the company to commercialize the vaccine, first in Switzerland and then in seven other countries in Eastern Europe. The OncoVAX vaccine represents a potential medical breakthrough because it uses a patient's own cancer cells to prevent the cancer from returning after a successful operation to remove it.

"This manufacturing license being granted by the most stringent and respected biotech manufacturing reviewers in Europe is a major milestone for Vaccinogen as it begins to generate revenues from OncoVAX," Dr. Hanna said. "It's also a major leap towards the worldwide acceptance of individualized cancer vaccines."

About OncoVAX

OncoVAX immunotherapy is based on a decades-long attempt by scientists to transform the body's immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases.

About Vaccinogen

Vaccinogen is a biopharmaceutical company that develops and commercializes cancer vaccines and other immunotherapeutic products -- Turning Cancer on Itself(TM). Based in Frederick, MD, the company has a portfolio of product candidates for the treatment of cancer, infectious disease, autoimmune, anti-inflammatory diseases and fully human monoclonal antibodies in various stages of clinical development.

Vaccinogen's online press kit:


Andrew L. Tussing



SOURCE Vaccinogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Highly Promising Dutch Research Into Alzheimers Disease and Parkinsons Disease
2. AOA President Calls on Congress to Reauthorize SCHIP and Take Action to Ensure Health Care Coverage for All Americans
3. Childrens Hospitals in Washington to Lobby Congress to Reauthorize SCHIP Now
4. American Physicians Capital, Inc. Authorizes Additional $20 Million Share Buyback
5. QLT Board authorizes exploration of strategic alternatives to enhance near- to mid-term shareholder value
6. Equity Research Firm Issued Unauthorized Report and Press Release on Immunosyn Corporation Today
7. Aflac Incorporated to Accelerate Share Repurchase in 2008; Authorizes Additional Share Repurchase and Increases Quarterly Cash Dividend 17.1%
8. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
9. Congress Poised to Reauthorize Legislation Aimed at Dramatic Expansion of Global HIV and AIDS Programs
10. Varian, Inc. Board Authorizes New $100 Million Stock Repurchase Program
11. 5,000 Northern California Nurses to Vote to Authorize Third Strike Against Sutter Chain
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... optimization of adjunctive imaging is the focus of numerous abstracts accepted for presentation ... 29-December 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative ...
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. (December ... the organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis ... celebrates exceptional special needs providers that excel in synthesizing the areas of clinical ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), a ... health arenas, is pleased to announce that VIP Care Services, a Caprock Health ... the ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , users ... over customization, the possibilities are truly endless, all with a click of a mouse. ... vertical flip, horizontal flip, depth of field and more, all within Final Cut Pro ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., announced today ... status from Cisco. This designation recognizes Tympani as having fulfilled the training requirements ... targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, President of ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Colo. , Dec. 1, 2015 /PRNewswire/ ... ) today announced that its Chief Executive ... at the Oppenheimer Annual Healthcare Conference in ... participate in the conference through a webcast ... , --> ...
(Date:12/1/2015)... , Dec. 1, 2015 Pharma Tech ... Top 10 Clinical Data Management Solution Providers - ... a distinguished panel comprising CEOs, CIOs, VCs, analysts, and ... the illustrious list of top 10 clinical data management ... article on pages 14 and 36 respectively). ...
(Date:12/1/2015)... de diciembre de 2015  AccuTEC Blades, ... de precisión, develó hoy un nuevo logo ... marca. El nuevo logo destaca la experiencia ... ingeniería de productos con cuchillas donde "el ... --> ...
Breaking Medicine Technology: